TheEdgeResearch
Home / Stocks / ARUXF

Acrux Limited (ARUXF)

OTC Healthcare Biotechnology
$0.01 ▲ +0.00%
Market Cap
$2.4M
Sector
Healthcare
Industry
Biotechnology
Beta
0.97
52-Wk Range
0.000099999997-0.0504
CEO
John Warmbrunn
Country
AU
Currency
USD

Acrux Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in West Melbourne, VIC, AU. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $2.4M. On trailing twelve-month figures it carries a trailing P/E of -7.14, a net margin of -13.0%. Its beta of 0.97 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-7.14
Price / Sales
1.32
Price / Book
2.86
EV / EBITDA
-4.08
Gross margin
90.6%
Operating margin
-46.1%
Net margin
-13.0%
Return on equity
—
Debt / equity
1.72
Current ratio
1.37
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
43
IPO date
2010-06-08
Headquarters
West Melbourne, VIC, AU
About Acrux Limited

Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.

Comparable companies

Acrux Limited is most often compared with the following Healthcare names:

AGNPFAXIMHAVLFIBOGFPKTXRDDTFREPCFRNUGFSIGYZLDAF
More research on ARUXF
ARUXF technical analysis ARUXF TheEdge Score Compare against peers
Open full interactive analysis & DCF →